The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
Infant Bacterial Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.63% SEK96.60
America/New_York / 17 mai 2024 @ 11:29
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 257.55 mill |
| EPS: | -10.08 |
| P/E: | -9.58 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 13.02 mill |
| Avg Daily Volume: | 0.0059 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.58 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -9.58 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK26.66 (-72.40%) SEK-69.94 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 92.22 - 100.98 ( +/- 4.54%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK96.60 (0.63% ) |
| Volume | 0.0019 mill |
| Avg. Vol. | 0.0059 mill |
| % of Avg. Vol | 31.87 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IBT-B.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IBT-B.ST
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.